[Biosimilars: Italian Medicines Agency takes position.]
The Italian Medicines Agency issued a new position paper on biosimilars that clarified several points regarding their correct use. This is a document that has the intent to promote the correct use and prescription of these medicines by answering some of the frequent questions coming from patients and prescribers. The debate surrounding the use of biosimilars is far from being concluded. However, some aspects, such as those regarding the quality, the safety and the efficacy of biosimilars, as well as the possibility of prescribe biosimilars not only to naïve patients naïve, it seems to be well supported. According to the new AIFA's position paper, the prescriber need to be the principal decision makers in the choice between biological and biosimilar. In the future, it will be interesting to check how much these new concepts will be able to influence, in current practice, the correct use of drugs that are presented as an important therapeutic resource for the National Health Service.